Jul 15, 2009
By: Ophthalmology Times Staff Reports
Ophthalmology Times E-News
The company recently reviewed interim efficacy and safety data from more than 200 patients in a large, controlled phase II trial. The findings confirmed previous pilot clinical results that anecortave acetate applied through a single anterior juxtascleral injection measurably reduced IOP for an extended period of time, according to a prepared statement.
Based on detailed analysis of the data, however, and after gaining input from a panel of expert clinical advisers, the company said it determined that the amount of IOP reduction and the response rate provided by even the highest dose were not sufficient to support the novel approach as a viable way to address the problem of patient adherence with eye drop therapy.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment